Wells Fargo initiated coverage on Infinity Pharmaceutical (NASDAQ: INFI) with an Outperform rating and a price target of $48-$50.

This article: 137 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE